WASHINGTON -- Congress is expected to change the criteria for advisers reviewing new medicines because of complaints that the rules that are meant to prevent conflicts of interest make it more difficult to find such experts.
Federal lawmakers may require the Food and Drug Administration to relax the rules that bar advisers from reviewing a drug if they have even indirect financial ties to related manufacturers.
Some senators raised the issue during a recent hearing held by the Health, Education, Labor and Pensions Committee.
Fees from makers of drugs and medical devices provide more than a third of the FDA's funding.
The agency frequently delays …
No comments:
Post a Comment